---
title: "Curis, Inc. (CRIS.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/CRIS.US.md"
symbol: "CRIS.US"
name: "Curis, Inc."
industry: "Biotechnology"
datetime: "2026-04-17T08:40:08.694Z"
locales:
  - [en](https://longbridge.com/en/quote/CRIS.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/CRIS.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/CRIS.US.md)
---

# Curis, Inc. (CRIS.US)

## Company Overview

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes. The company’s pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small-molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreements with Genentech Inc., or Genentech and F.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.curis.com](https://www.curis.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-04-17T04:30:12.000Z

**Overall: C (0.58)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 189 / 393 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -13.43% |  |
| Net Profit YoY | 82.53% |  |
| P/B Ratio | 4.33 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 23631405.43 |  |
| Revenue | 9443000.00 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 2829.10% | A |
| Profit Margin | -80.29% | E |
| Gross Margin | -199.68% | E |
| Revenue YoY | -13.43% | E |
| Net Profit YoY | 82.53% | A |
| Total Assets YoY | -51.62% | E |
| Net Assets YoY | 191.06% | A |
| Cash Flow Margin | 358.76% | A |
| OCF YoY | -13.43% | E |
| Turnover | 0.31 | D |
| Gearing Ratio | 72.64% | D |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Curis, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-13.43%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "82.53%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "4.33",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "23631405.43",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "9443000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "2829.10%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "-80.29%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "-199.68%",
          "rating": "E"
        },
        {
          "name": "Revenue YoY",
          "value": "-13.43%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "82.53%",
          "rating": "A"
        },
        {
          "name": "Total Assets YoY",
          "value": "-51.62%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "191.06%",
          "rating": "A"
        },
        {
          "name": "Cash Flow Margin",
          "value": "358.76%",
          "rating": "A"
        },
        {
          "name": "OCF YoY",
          "value": "-13.43%",
          "rating": "E"
        },
        {
          "name": "Turnover",
          "value": "0.31",
          "rating": "D"
        },
        {
          "name": "Gearing Ratio",
          "value": "72.64%",
          "rating": "D"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -3.12 | 305/393 | - | - | - |
| PB | 4.33 | 293/393 | 4.02 | 3.90 | 1.86 |
| PS (TTM) | 2.50 | 61/393 | 1.94 | 1.69 | 1.17 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Rigel Pharma (RIGL.US) | A | A | B | B | B | A |
| 03 | MiMedx (MDXG.US) | A | B | A | B | B | A |
| 04 | Vertex Pharma (VRTX.US) | A | B | C | B | C | B |
| 05 | Regeneron Pharma (REGN.US) | A | C | C | B | C | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-04-06T04:00:00.000Z

Total Analysts: **4**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 3 | 75% |
| Overweight | 1 | 25% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 0.59 |
| Highest Target | 20.00 |
| Lowest Target | 5.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/CRIS.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/CRIS.US/norm.md)
- [Related News](https://longbridge.com/en/quote/CRIS.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/CRIS.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**